Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy

  • Yun, Yuni (Department of Pediatrics, School of Medicine, Kyungpook National University) ;
  • Kim, Dongsub (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Yun-Jeong (Department of Pediatrics, School of Medicine, Kyungpook National University) ;
  • Kwon, Soonhak (Department of Pediatrics, School of Medicine, Kyungpook National University) ;
  • Hwang, Su-Kyeong (Department of Pediatrics, School of Medicine, Kyungpook National University)
  • Received : 2018.08.14
  • Accepted : 2018.12.26
  • Published : 2019.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: There is limited data on the use of perampanel in children under 12 years of age. We evaluated the efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy. Methods: This retrospective observational study was performed in Kyungpook National University Hospital from July 2016 to March 2018. A responder was defined as a patient with ${\geq}50%$ reduction in monthly seizure frequency compared with the baseline. Adverse events and discontinuation data were obtained to evaluate tolerability. Results: Twenty-two patients (8 males, 14 females) aged 3.1-11.4 years (mean, $8.0{\pm}2.5years$) were included in this study. After an average of 9.2 months (range, 0.5-19 months) of follow-up, 15 patients (68%) showed a reduction in seizure frequency, including 5 patients (23%) with seizure freedom. The age at epilepsy onset was significantly lower (P=0.048), and the duration of epilepsy was significantly longer (P=0.019) in responders than in nonresponders. Nine patients (41%) experienced adverse events, including somnolence (23%), respiratory depression (9%), violence (4.5%), and seizure aggravation (4.5%). The most serious adverse event was respiratory depression, which required mechanical ventilation in 2 patients (9%). Eight patients (36%) discontinued perampanel due to lack of efficacy or adverse events. Three out of 4 patients (75%) who discontinued perampanel due to adverse events had an underlying medical condition. Conclusion: Perampanel offers a treatment option for refractory epilepsy in children. Adjunctive treatment with perampanel requires special consideration in those with underlying medical conditions to prevent serious adverse events.

Keywords

References

  1. Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 2010;19:650-5. https://doi.org/10.1016/j.seizure.2010.10.027
  2. Loscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52:657-78. https://doi.org/10.1111/j.1528-1167.2011.03024.x
  3. Rudzinski LA, Velez-Ruiz NJ, Gedzelman ER, Mauricio EA, Shih JJ, Karakis I. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel. J Investig Med 2016;64:1087-101. https://doi.org/10.1136/jim-2016-000151
  4. Plosker GL. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs 2012;26:1085-96. https://doi.org/10.1007/s40263-012-0021-2
  5. Shih JJ, Tatum WO, Rudzinski LA. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Ther Clin Risk Manag 2013;9:285-93. https://doi.org/10.2147/TCRM.S37317
  6. Gidal BE, Laurenza A, Hussein Z, Yang H, Fain R, Edelstein J, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology 2015;84:1972-80. https://doi.org/10.1212/WNL.0000000000001558
  7. De Liso P, Moavero R, Coppola G, Curatolo P, Cusmai R, De Sarro G, et al. Current role of perampanel in pediatric epilepsy. Ital J Pediatr 2017;43:51. https://doi.org/10.1186/s13052-017-0368-6
  8. Swiderska N, Tan HJ, Rajai A, Silwal A, Desurkar A, Martland T. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study. Seizure 2017;52:63-70. https://doi.org/10.1016/j.seizure.2017.08.014
  9. Falco-Walter JJ, Scheffer IE, Fisher RS. The new definition and classification of seizures and epilepsy. Epilepsy Res 2018;139:73-9. https://doi.org/10.1016/j.eplepsyres.2017.11.015
  10. Biro A, Stephani U, Tarallo T, Bast T, Schlachter K, Fleger M, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics 2015;46:110-6. https://doi.org/10.1055/s-0035-1546276
  11. De Liso P, Vigevano F, Specchio N, De Palma L, Bonanni P, Osanni E, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study. Epilepsy Res 2016;127:93-100. https://doi.org/10.1016/j.eplepsyres.2016.08.021
  12. Heyman E, Lahat E, Levin N, Epstein O, Lazinger M, Berkovitch M, et al. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol 2017;59:441-4. https://doi.org/10.1111/dmcn.13362
  13. Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partialonset seizures. Epilepsia 2013;54:1490-7. https://doi.org/10.1111/epi.12240
  14. Kwan P, Brodie MJ, Laurenza A, FitzGibbon H, Gidal BE. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes. Epilepsy Res 2015;117:117-24. https://doi.org/10.1016/j.eplepsyres.2015.09.002
  15. Wirrell E, Wong-Kisiel L, Mandrekar J, Nickels K. Predictors and course of medically intractable epilepsy in young children presenting before 36 months of age: a retrospective, population-based study. Epilepsia 2012;53:1563-9. https://doi.org/10.1111/j.1528-1167.2012.03562.x

Cited by

  1. Perampanel is also a useful adjunctive treatment option in refractory epilepsy in children vol.62, pp.7, 2019, https://doi.org/10.3345/kjp.2019.00108
  2. Perampanel : Various toxicities: 9 case reports vol.1774, pp.1, 2019, https://doi.org/10.1007/s40278-019-68712-3